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Abstract
BACKGROUND—Dry eye disease is a common chronic condition that is characterized by ocular 
discomfort and visual disturbances that decrease quality of life. Many clinicians recommend the 
use of supplements of n–3 fatty acids (often called omega-3 fatty acids) to relieve symptoms.
METHODS—In a multicenter, double-blind clinical trial, we randomly assigned patients with 
moderate-to-severe dry eye disease to receive a daily oral dose of 3000 mg of fish-derived n–3 
eicosapentaenoic and docosahexaenoic acids (active supplement group) or an olive oil placebo 
(placebo group). The primary outcome was the mean change from baseline in the score on the 
Ocular Surface Disease Index (OSDI; scores range from 0 to 100, with higher scores indicating 
greater symptom severity), which was based on the mean of scores obtained at 6 and 12 months. 
Secondary outcomes included mean changes per eye in the conjunctival staining score (ranging 
from 0 to 6) and the corneal staining score (ranging from 0 to 15), with higher scores indicating 
more severe damage to the ocular surface, as well as mean changes in the tear break-up time 
(seconds between a blink and gaps in the tear film) and the result on Schirmer’s test (length of 
wetting of paper strips placed on the lower eyelid), with lower values indicating more severe signs.
RESULTS—A total of 349 patients were assigned to the active supplement group and 186 to the 
placebo group; the primary analysis included 329 and 170 patients, respectively. The mean change 
in the OSDI score was not significantly different between the active supplement group and the 
placebo group (−13.9 points and −12.5 points, respectively; mean difference in change after 
imputation of missing data, −1.9 points; 95% confidence interval [CI], −5.0 to 1.1; P=0.21). This 
result was consistent across prespecified subgroups. There were no significant differences between 
the active supplement group and the placebo group in mean changes from baseline in the 
conjunctival staining score (mean difference in change, 0.0 points; 95% CI, −0.2 to 0.1), corneal 
staining score (0.1 point; 95% CI, −0.2 to 0.4), tear break-up time (0.2 seconds; 95% CI, −0.1 to 
0.5), and result on Schirmer’s test (0.0 mm; 95% CI, −0.8 to 0.9). At 12 months, the rate of 
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adherence to treatment in the active supplement group was 85.2%, according to the level of n–3 
fatty acids in red cells. Rates of adverse events were similar in the two trial groups.
CONCLUSIONS—Among patients with dry eye disease, those who were randomly assigned to 
receive supplements containing 3000 mg of n–3 fatty acids for 12 months did not have 
significantly better outcomes than those who were assigned to receive placebo. (Funded by the 
National Eye Institute, National Institutes of Health; DREAM ClinicalTrials.gov number, 
NCT02128763.)
Dry eye disease (also known as kera-toconjunctivitis sicca) is a common chronic, 
inflammatory, age-related condition that causes ocular discomfort, fatigue, and visual 
disturbances that interfere with reading, computer use, driving, and other aspects of quality 
of life.1–3 The prevalence of symptomatic dry eye disease among adults in the United States 
is approximately 14%; rates are higher among women and increase with age.4 Dry eye 
disease is one of the most common reasons for seeking eye care.2 When the costs of medical 
care and productivity loss are combined, the annual cost to the U.S. economy is more than 
$55 billion.5 Patients with dry eye disease use a variety of approaches for symptom relief, 
including artificial tears, lid scrubs, punctal plugs, and prescription antiinflammatory 
eyedrops. Many clinicians recommend and many patients take dietary supplements of n–3 
fatty acids (often called omega-3 fatty acids), because they have antiinflammatory activity 
and are not associated with substantial side effects.6
There is no definitive evidence of the efficacy of n–3 fatty acid supplements in the relief of 
symptoms or in the resolution of signs of dry eye disease. The American Academy of 
Ophthalmology Preferred Practice Pattern guidelines state that n–3 fatty acid products may 
be beneficial, “though the evidence is insufficient to establish the effectiveness.”7 The Dry 
Eye Assessment and Management (DREAM) trial was designed to provide comprehensive 
information on the effects of n–3 fatty acid supplementation on dry eye disease.
METHODS
TRIAL POPULATION
From October 2014 through July 2016, a total of 923 patients completed a screening visit at 
27 clinical centers in the United States (Fig. S1 in the Supplementary Appendix, available 
with the full text of this article at NEJM.org). At the screening visit, 678 patients (73.5%) 
met none of the exclusion criteria; these patients were provided with run-in supplements 
(placebo capsules) and were scheduled to attend an eligibility-confirmation visit 
approximately 2 weeks later. Of the 615 patients who returned for the eligibility-
confirmation visit, 535 (87.0%) were eligible for inclusion in the trial.
The trial was designed to include a broad spectrum of patients with symptomatic moderate-
to-severe dry eye disease. Eligibility criteria were an age of 18 years or older, the presence 
of ocular symptoms related to dry eye disease for at least 6 months, the use of or a desire to 
use artificial tears an average of at least two times per day during the 2 weeks before the 
screening visit, and a score on the Ocular Surface Disease Index (OSDI) of 25 to 80 at the 
screening visit and of 21 to 80 at the eligibility-confirmation visit. Scores on the 12-item 
OSDI range from 0 to 100, with a score of 0 indicating no ocular discomfort and higher 
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scores indicating greater symptom severity. The minimal clinically meaningful change in 
score is 10 points.8,9 Scores on three subscales of the OSDI (ocular symptoms, vision-
related function, and environmental triggers) also range from 0 to 100, with higher scores 
indicating greater symptom severity.
In addition, patients had to have at least two of the following four signs in at least one eye: a 
conjunctival lissamine-green staining score of 1 or more (on a scale ranging from 0 to 6, 
with higher scores indicating greater abnormality), a corneal fluorescein staining score of 4 
or more (on a scale ranging from 0 to 15, with higher scores indicating greater abnormality), 
a tear break-up time (the time from a blink to the appearance of gaps in the tear film, with 
shorter times indicating greater abnormality) of 7 seconds or less, and a result on Schirmer’s 
test with anesthesia (the length of wetting of paper strips placed in the inferior cul de sac of 
the lower eyelid, with shorter lengths indicating greater abnormality) of 1 to 7 mm in 5 
minutes. The same qualifying signs had to be present in the same eye at both the screening 
visit and the eligibility-confirmation visit.
Patients were excluded from the trial if they did not take at least 90% of the run-in 
supplements (five per day) or if they had worn contact lenses during the 30 days before the 
screening visit, had undergone laser-assisted in situ keratomileusis or recent ocular surgery 
(within the past 6 months), or had a history of ocular infection or contraindications to 
treatment with high-dose n–3 fatty acid supplementation (see the Supplementary Appendix 
and the protocol, available at NEJM.org). Patients who were regularly using treatments for 
dry eye disease (including n–3 fatty acid supplements: eicosapentaenoic acid [EPA] plus 
docosahexaenoic acid [DHA] at a dose of <1200 mg daily), systemic medications that are 
known to cause ocular dryness, systemic glucocorticoids, or other immunosuppressive 
agents were allowed to continue those treatments if they committed to using them for the 
next 12 months. Patients with a history of thyroid disease, Sjögren’s syndrome, rheumatoid 
arthritis, or inflammatory diseases could be included in the trial if they were otherwise 
eligible.
The DREAM Study Research Group had control of the design and conduct of the trial and 
the interpretation of the data. The protocol was approved by the institutional review board at 
each center, and the trial was carried out under a Food and Drug Administration 
Investigational New Drug application. The first four members of the writing committee 
vouch for the accuracy and completeness of the data and the fidelity of the trial to the 
protocol. All the patients provided written informed consent.
TRIAL GROUPS
Patients were randomly assigned, in a 2:1 ratio, to receive active or placebo supplements for 
12 months. Randomization was performed with the use of a Web-based module and was 
stratified according to clinical center with a permuted-block method with randomly chosen 
block sizes. Personnel at the Investigational Drug Service, University of Pennsylvania, 
mailed the supplements directly to the patients.
In both trial groups, the regimen was five soft-gelatin capsules per day. Each active capsule 
contained 400 mg of EPA and 200 mg of DHA, for a total daily dose of 2000 mg of EPA and 
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1000 mg of DHA. Each placebo capsule contained 1000 mg of refined olive oil; each 
capsule was 68% oleic acid, 13% palmitic acid, and 11% linoleic acid. The active and 
placebo capsules contained 3 mg of vitamin E (alpha-tocopherol), as an antioxidant, as well 
as masking flavor and lemon flavor. The Access Business Group manufactured and donated 
the capsules. The fish oil concentrate in triglyceride form that was included in the active 
supplements was donated by Epax. The contents of the active and placebo capsules were 
verified by an independent laboratory (Nutra-source Diagnostics). The regimen was reduced 
or suspended when the patient reported gastrointestinal symptoms or when a 
contraindication to treatment with the full dose of active supplements developed. With 
resolution of symptoms or contraindications, the patient could restart or increase the 
regimen.
OUTCOME MEASURES
The primary outcome was the mean change from baseline in the OSDI score. The following 
measures were prespecified secondary outcomes: the proportion of patients with a decrease 
from baseline in the OSDI score of 10 points or more, changes in the percentages of EPA 
and DHA in total fatty acids in red cells (by weight), changes in signs of dry eye disease (as 
assessed by conjunctival staining score, corneal staining score, tear break-up time, and the 
result on Schirmer’s test), changes in the scores on the physical health and mental health 
subscales of the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36; scores 
range from 0 to 100, with higher scores indicating better health-related quality of life), 
changes in the scores on the discomfort and pain interference subscales of the Brief Ocular 
Discomfort Index (BODI; scores range from 0 to 100, with higher scores indicating greater 
discomfort), changes in treatments used for dry eye disease, changes in visual acuity and 
intraocular pressure (safety outcomes), and the incidence of adverse events. Coordinators 
asked patients about adverse events during each visit (at 3, 6, and 12 months) and by 
telephone (at 9 months) and coded these events according to the Medical Dictionary for 
Regulatory Activities (MedDRA) system; a medical monitor reviewed serious adverse 
events and their codes. All patients, clinical staff, and laboratory personnel were unaware of 
the trial-group assignments.
RPS Diagnostics provided their InflammaDry Detector test kits, TearLab provided materials 
for their TearLab Osmolarity System, and Tear-Science provided their Meibomian Gland 
Evaluators at a discounted cost. Results of these tests were used to define subgroups for 
analyses shown in the Supplementary Appendix.
STATISTICAL ANALYSIS
For the primary and secondary outcomes, baseline values were the means of values obtained 
during the screening and eligibility-confirmation visits, except for values obtained only 
during the eligibility-confirmation visit (e.g., visual acuity and results of impression 
cytology). The values used for assessing change were the means of values obtained during 
the 6-month and 12-month visits; if a value from only one of these visits was available, that 
value was used. The 97.5 percentile for the mean change from baseline in the EPA level at 6 
months in the placebo group (0.32 percentage points) was used as a threshold for adherence 
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to treatment in the active supplement group. Analyses were performed according to the 
intention-to-treat principle.
Comparisons of the mean change in continuous measures between trial groups and 
associated 95% confidence intervals were based on linear regression with a robust variance 
estimator. Generalized estimating equations were used for ocular measures to accommodate 
the correlation between eyes in the same person.10 Propensity scores and the regression 
method of multiple imputation were used for missing OSDI scores at month 6 or 12.11 In 
accordance with the protocol, an analysis of the mean change in the OSDI score with 
adjustment for the baseline EPA level was performed because of an imbalance between trial 
groups in the EPA level (P<0.10). Comparisons of categorical outcomes were based on chi-
square tests, and 95% confidence intervals for the difference in proportions were calculated 
with the Wilson method.12 Differences between trial groups in the cumulative proportion of 
patients with an adverse event were evaluated with the log-rank test; Fisher’s exact test was 
used when the number of patients in a group with a given adverse event was 5 or fewer. The 
significance of differences between trial groups for 18 secondary outcomes, measures of 
adherence to the trial regimen, and safety measures were evaluated with post hoc application 
of the Benjamini–Hochberg adjustment.
Prespecified subgroups were defined according to baseline severity of symptoms (OSDI 
score ≥40 vs. <40), severity of signs (severe [conjunctival staining score, ≥2; corneal 
staining score, ≥4; tear break-up time, <5 seconds; and the result on Schirmer’s test, ≤7 mm 
in 5 minutes] vs. not severe), EPA and DHA levels in red cells (both levels above vs. one or 
both levels equal to or below the mean levels in the reference population of the central 
laboratory [DHA, 3.7%; EPA, 0.6%]), and ocular inflammation (0 vs. 1 vs. 2 eyes with a 
percentage of HLA-DR+ epithelial cells on impression cytology that was greater than the 
median percentage among all patients in the trial [5%]). Tests of interaction were used to 
evaluate whether the effect of supplementation with n–3 fatty acids differed among 
subgroups.
We determined that a sample of 505 patients would provide the trial with 90% statistical 
power to detect a 6-point mean difference between trial groups in the mean change in the 
OSDI score, assuming a standard deviation of 18 points and missing data for 15% of 
patients. This report includes data that were available by October 24, 2017. Statistical 
computations were performed with SAS software, version 9.4 (SAS Institute).
RESULTS
PATIENTS AND ADHERENCE
A total of 349 patients were assigned to the active supplement group and 186 to the placebo 
group. There were no significant imbalances between trial groups in baseline characteristics, 
except for the higher mean EPA level in the active supplement group than in the placebo 
group (0.63% vs. 0.56%; P = 0.047) (Table 1, and Table S1 in the Supplementary 
Appendix). A total of 974 of the 1044 scheduled follow-up visits (93.3%) were completed in 
the active supplement group, and 498 of the 558 visits (89.2%) were completed in the 
placebo group. The change in the mean EPA level was 2.2 percentage points in the active 
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supplement group as compared with 0.0 percentage points in the placebo group (P<0.001); 
the change in the mean DHA level was 1.6 percentage points as compared with −0.1 
percentage points (P<0.001), and the change in the mean oleic acid level was −0.1 
percentage points and 0.1 percentage points, respectively (P = 0.40) (Table 2). In the active 
supplement group, for 264 of the 290 patients who were assessed at 6 months (91.0%) and 
for 247 of the 290 patients who were assessed at 12 months (85.2%), the EPA level exceeded 
the threshold for adherence to treatment. At 12 months, 269 of 324 patients in the active 
supplement group (83.0%) and 136 of 164 patients in the placebo group (82.9%) reported 
taking five capsules daily.
OUTCOMES
OSDI scores decreased between baseline and 12 months in the active supplement group and 
in the placebo group (P<0.001 for change in each group); most of the decrease was during 
the first 3 months (Fig. 1). The mean (±SD) change in the total OSDI score was −13.9±15.6 
points in the active supplement group and −12.5±18.2 points in the placebo group, resulting 
in a mean difference in change of −1.9 points (95% confidence interval [CI], −5.0 to 1.1; P = 
0.21) in an analysis performed with the regression method of multiple imputation for 
missing data (Table S2 in the Supplementary Appendix). The mean difference in change was 
−1.4 points (95% CI, −4.6 to 1.8; P = 0.40) in an analysis performed without multiple 
imputation (which included 499 patients) and was −1.6 points (95% CI, −4.8 to 1.6; P = 
0.32) in an analysis performed with adjustment for the baseline EPA level (which included 
486 patients) (Table 2). The mean changes in scores on the three OSDI subscales were not 
significantly different in the two trial groups (P≥0.10 for all comparisons).
The 4 prespecified subgroup analyses did not reveal any significant interactions (P≥0.29 for 
all comparisons) (Table 3). Within subgroups, the estimated mean differences in change in 
the OSDI score between trial groups did not exceed 3.3 points. In addition, 18 exploratory 
analyses of subgroups defined according to baseline demographic characteristics, use of 
medications, systemic diseases, signs of dry eye disease, candidate biomarkers for dry eye 
disease, use of n–3 fatty acid supplements, and self-reported adherence did not reveal any 
significant interactions (Table S3 in the Supplementary Appendix). The changes in 
secondary outcome measures were similar in the two trial groups (Table 2). In each trial 
group, there were improvements between baseline and 12 months in the conjunctival 
staining score, the corneal staining score, and the tear break-up time (P<0.001 for change for 
each measure in each group) but not in the result on Schirmer’s test (P = 0.79 for change in 
the active supplement group; P = 0.46 for change in the placebo group) (Fig. 2). Changes in 
these signs were not significantly different in the two trial groups (P≥0.25 for all 
comparisons) (Table 2), as were the changes in mean visual acuity and mean intraocular 
pressure.
ADVERSE EVENTS
The percentage of patients with at least one serious adverse event was 6.0% in the active 
supplement group and 8.1% in the placebo group (P = 0.31). The percentage of patients with 
at least one nonserious adverse event was similar in the active supplement group and the 
placebo group (61.9% and 60.8%, respectively; P = 0.87), as was the percentage of patients 
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with an episode of bleeding (2.0% and 1.6%, respectively; P = 1.00). A higher percentage of 
patients reported diarrhea in the active supplement group than in the placebo group (4.9% 
and 1.6%, respectively; P = 0.09) (Tables S4 and S5 in the Supplementary Appendix).
DISCUSSION
In this randomized, multicenter clinical trial of 12 months of daily oral supplementation with 
3000 mg of n–3 fatty acids for the treatment of dry eye disease, symptoms and signs 
improved both among patients who received the active supplement and among those who 
received placebo, and there was no significant difference in improvement between the two 
groups. The mean OSDI score decreased (improved) significantly, by approximately 13 
points, in each group during follow-up, with greater improvement by 1.9 points (95% CI, 
−5.0 to 1.1; P = 0.21) in the active supplement group than in the placebo group. There was 
virtually no difference between the two groups in the improvement in four key signs of dry 
eye disease (P≥0.25 for all comparisons) (Table 2).
Several fundamental aspects of the design and conduct of the DREAM trial contribute to the 
validity and generalizability of the results. This trial was a “real world” clinical trial, 
including patients with typical dry eye disease who sought relief of symptoms despite the 
use of other interventions. Patients were recruited from private and academic optometry and 
ophthalmology practices throughout the United States and had symptoms and signs of 
moderate-to-severe dry eye disease on two consecutive examinations that were performed 2 
weeks apart. Patients were allowed to continue their current treatments for dry eye disease, 
which is not the case in most industry-sponsored trials of treatments for this disease. Eye 
examinations were conducted according to a standard protocol by trial-certified staff to 
reduce variation between visits and examiners. The 1-year follow-up period minimized the 
effect of seasonal factors. The dose of n–3 fatty acids (3000 mg daily) was the highest dose 
used in previous clinical trials of fish-derived n–3 fatty acids. The daily placebo was 
approximately 1 teaspoon of olive oil, which primarily delivers n–9 oleic acid, a substance 
that is considered to be neutral with respect to changes in symptoms and signs of dry eye 
disease. An independent laboratory verified the fatty acid composition of the supplements. 
The change in the n–3 fatty acid level, as measured in red-cell membranes, indicated a high 
level of adherence to treatment among patients in the active supplement group; the mean 
EPA level increased by 400% in the active supplement group, whereas the mean oleic acid 
level changed by less than 1% in either trial group. The percentage of completed follow-up 
visits was high (93.3% in the active supplement group and 89.2% in the placebo group). As 
in other clinical trials of treatments for dry eye disease, the placebo effect was substantial.
13,14
 Results from the analysis of the primary outcome (mean change in the OSDI score), 
prespecified subgroup analyses, and analyses of all the secondary outcomes consistently 
showed a difference between the active supplement group and the placebo group that was 
small and not significant.
Direct comparison of the results of the DREAM trial with the results of previous 
randomized, placebo-controlled clinical trials of n–3 fatty acids for dry eye disease is 
complicated by differences in eligibility criteria, n–3 fatty acid dose, placebo content, 
duration of supplementation, criteria regarding the use of other treatments for dry eye 
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disease, dietary practices of the participants (e.g., diet in India), and outcome measures.15–27 
Aside from several large trials that were conducted in India by Bhargava et al.,15–18 the 
previous clinical trials involved fewer than 125 total patients. Most of these trials showed 
significantly greater improvement in symptoms or in at least one of several signs of dry eye 
disease in the n–3 fatty acid group than in the placebo group.15,18–22,24,26 Some studies had 
highly restrictive eligibility criteria. For example, of the 375 patients in the DREAM trial 
who had tear osmolarity measurements, only 24 (6.4%) would have met the following 
eligibility criteria in a recent study: an osmolarity of at least 312 mOsm per milliliter in at 
least one eye and mild meibomian-gland dysfunction in both eyes.20 Other studies included 
only patients with rosacea17 or with results on Schirmer’s test of less than 5 mm in 5 
minutes.22 In the DREAM trial, analyses of subgroups that were defined according to these 
and other criteria did not yield evidence of a benefit from treatment as compared with 
placebo.
In conclusion, among patients who had moderate-to-severe dry eye disease despite the use of 
other treatments and were randomly assigned to receive either n–3 fatty acid or placebo 
supplements, symptoms and signs had improved. We found no evidence of a beneficial 
effect of n–3 fatty acid supplements as compared with placebo supplements among patients 
with dry eye disease.
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Figure 1. Distribution of Scores on the Ocular Surface Disease Index
Shown are box-and-whisker plots of the scores on the Ocular Surface Disease Index (OSDI) 
in the active supplement group (who received a daily capsule of 3000 mg of n–3 fatty acids) 
and the placebo group between baseline and 12 months. The upper and lower edges of the 
boxes correspond to the 75th and 25th percentiles, respectively. Within the boxes, the 
asterisks correspond to the mean and the lines correspond to the 50th percentile (median). 
The upper and lower ends of the whiskers correspond to the highest score within 1.5× the 
interquartile range of the 75th percentile and the lowest score within 1.5× the interquartile 
range of the 25th percentile, respectively. Each dot outside the whiskers corresponds to one 
score.
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Figure 2. Change in Signs of Dry Eye Disease
The following results constitute signs of dry eye disease in an eye: a conjunctival lissamine-
green staining score of 1 or more (on a scale ranging from 0 to 6, with higher scores 
indicating greater abnormality), a corneal fluorescein staining score of 4 or more (on a scale 
ranging from 0 to 15, with higher scores indicating greater abnormality), a tear break-up 
time (the time from a blink to the appearance of gaps in the tear film, with shorter times 
indicating greater abnormality) of 7 seconds or less, and a result on Schirmer’s test with 
anesthesia (the length of wetting of paper strips placed in the inferior cul de sac of the lower 
eyelid, with shorter lengths indicating greater abnormality) of 1 to 7 mm in 5 minutes. In 
each trial group, there was a significant change between baseline and 12 months (with time 
as a continuous variable) in the conjunctival staining score, the corneal staining score, and 
the tear break-up time (P<0.001 for change for each measure in each group) but not in the 
result on Schirmer’s test (P = 0.79 for change in the active supplement group; P = 0.46 for 
change in the placebo group).
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Table 1
Characteristics of the Patients at Baseline.*
Characteristic Active Supplement (N = 349) Placebo (N = 186)
Age — yr 58.3±13.5 57.5±12.6
Sex — no. (%)
 Female 284 (81.4) 150 (80.6)
 Male 65 (18.6) 36 (19.4)
Race — no. (%)†
 White 265 (75.9) 133 (71.5)
 Black 39 (11.2) 25 (13.4)
 Other 45 (12.9) 28 (15.1)
Ethnic group — no. (%)†
 Hispanic or Latino 44 (12.6) 24 (12.9)
 Other 305 (87.4) 162 (87.1)
OSDI score‡
 Total 44.6±14.0 44.1±14.6
 Vision-related function subscale 37.2±17.8 38.8±17.6
 Ocular symptoms subscale 47.4±16.5 45.0±18.2
 Environmental triggers subscale 56.5±23.9 53.8±25.4
Treatments used for dry eye disease — no. (%)
 Artificial tears, either drops or gel 277 (79.4) 147 (79.0)
 Cyclosporine drops 134 (38.4) 71 (38.2)
 Warm lid soaks 80 (22.9) 34 (18.3)
 Lid scrubs or baby shampoo 56 (16.0) 27 (14.5)
 Other 170 (48.7) 99 (53.2)
Fatty acid levels in red cells — %§
 Eicosapentaenoic acid¶ 0.63±0.43 0.56±0.35
 Docosahexaenoic acid 3.91±1.17 3.85±1.11
 Oleic acid 11.11±1.24 11.10±1.38
Signs of dry eye disease||
 Conjunctival staining score 3.1±1.4 2.9±1.4
 Corneal staining score 4.0±2.9 3.7±2.4
 Tear break-up time — sec 3.1±1.4 3.1±1.6
 Result on Schirmer’s test — mm in 5 minutes 9.3±6.2 10.2±7.0
*
Plus–minus values are means ±SD. Baseline values were the means of values obtained during the screening and eligibility-confirmation visits, 
except for values for fatty acid levels and treatments used for dry eye disease, which were obtained only at the eligibility-confirmation visit.
†
Race and ethnic group were reported by the patient.
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‡Ocular Surface Disease Index (OSDI) scores range from 0 to 100, with a score of 0 indicating no ocular discomfort and higher scores indicating 
greater symptom severity. The minimal clinically meaningful change in score is 10 points. Scores on three subscales of the OSDI (ocular 
symptoms, vision-related function, and environmental triggers) also range from 0 to 100, with higher scores indicating greater symptom severity.
§
Data are missing for 11 patients in the active supplement group and 4 patients in the placebo group.
¶
P = 0.047 for the mean difference between trial groups.
||
Data are from assessments of 665 eyes in the active supplement group and 357 eyes in the placebo group. The following results constitute signs of 
dry eye disease in an eye: a conjunctival lissamine-green staining score of 1 or more (on a scale ranging from 0 to 6, with higher scores indicating 
greater abnormality), a corneal fluorescein staining score of 4 or more (on a scale ranging from 0 to 15, with higher scores indicating greater 
abnormality), a tear break-up time (the time from a blink to the appearance of gaps in the tear film, with shorter times indicating greater 
abnormality) of 7 seconds or less, and a result on Schirmer’s test with anesthesia (the length of wetting of paper strips placed in the inferior cul de 
sac of the lower eyelid, with shorter lengths indicating greater abnormality) of 1 to 7 mm in 5 minutes.
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